France Nuclear Imaging - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

The France Nuclear Imaging Market size is estimated at USD 412.91 million in 2024, and is expected to reach USD 483.58 million by 2029, growing at a CAGR of 3.21% during the forecast period (2024-2029).

During the COVID-19 pandemic, the nuclear imaging market in France was significantly affected as a result of lockdown and restrictions on non-essential procedures. According to a study titled 'Quantitative impact of the first COVID-19 lockdown on nuclear medicine in France: the CORALINE study' published in the National Center for Biotechnology Information in June 2021, the total number of nuclear medicine examinations performed in France dropped by 43.4% in the time span of 4 weeks before and after the lockdown. However, after the COVID-19 pandemic, the market is gaining its momentum back. Therefore, it is observed that despite the decrease in utilization of nuclear imaging during the pandemic, the market is believed to witness steady growth in the coming years.

The studied market growth can largely be attributed to factors, such as the increasing prevalence of cancer and cardiac disorders, and technological advancements in nuclear imaging. Morover, according to the United Nations Population Fund's World Population Dashboard's Statistics 2021, in France, there are about 21.1% of people aged 65 years and above. As the older population is most likely to get affected by chronic diseases, the need for devices for monitoring, diagnosis, and treatment is expected to increase over the forecast period. Thereby boosting the growth of the market studied.

Additionally, technological advancements in nuclear imaging are augmenting the growth of the market studied in France. For instance, in May 2022, physicians from Baclesse Cancer Center, France demonstrated that an artificial intelligence (AI) program can enhance image quality in half-count F-18 FDG-PET scans, opening the door to large acquisition time reductions in standard clinical practice. With the findings from various studies, nuclear medicine specialists from France have started implementing advanced technologies in PET/SPECT scans which is expected to contribute to the growth of the market studied.

France Nuclear Imaging Market Trends

PET Radioisotopes are Expected to Witness Strong Growth in Future

The radioisotopes used in PET to label tracers are 11C, 13N, 150, and 18F (carbon, nitrogen, oxygen, and 18F are used as a substitute for hydrogen). The body will absorb these radioactive forms of natural elements, which the scanner will detect. These isotopes can be used to label a number of substances and medications.

The activities undertaken by key companies operating in the nuclear imaging market are fueling the growth of the segment. For instance, in March 2021, Eckert & Ziegler Radiopharma GmbH and Curium PET France decided to reinforce their existing long-term partnership by extending their agreement for the distribution of Galliapharm generators in France, Curium being the partner of choice given the national coverage of its PET network in France. Additionally, in August 2021, Curium submitted an Investigational New Drug (IND) application for Cu-64 PSMA I&T, a radiopharmaceutical that binds to Prostate-Specific Membrane Antigen (PSMA) for use with Positron Emission Tomography (PET), for the detection and localization of metastatic prostate cancer.

With the increasing involvement of key companies in PET radioisotope segment, it is expected that PET radioisotopes will be witnessing a healthy growth in coming years.

France Nuclear Imaging Industry Overview

The nuclear imaging market is highly competitive and consists of a few major players. In terms of market share, few of the major players currently dominate the market. Companies, like Bracco Imaging SpA, Curium, Cardinal Health Inc., Koninklijke Philips NV, GE Healthcare, and Siemens Healthineers, among others, hold a substantial share in the market.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support